# A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

> **NCT05745740** · PHASE1,PHASE2 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 26 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT05745740
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745740, "A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05745740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*